Significant Ownership of ORAMED PHARMACEUTICALS INC.

Signature - Title
/s/ Avraham Gabay - Avraham Gabay, Chief Financial Officer
Location
New York, NY
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by ORAMED PHARMACEUTICALS INC..

Notify me when ORAMED PHARMACEUTICALS INC. files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of ORAMED PHARMACEUTICALS INC.

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
DRTS Alpha Tau Medical Ltd. Ordinary shares, no par value 20% $37,250,719 14,110,121 Oramed Pharmaceuticals Inc. 24 Apr 2025
SCLX Scilex Holding Company Common Stock par value $0.0001 per share 9.9% $146,543 -$2,953,457 732,717 -95% Oramed Pharmaceuticals Inc. 31 Mar 2025
NNDM Nano Dimension Ltd. Ordinary Shares, par value NIS 5.00 per share 5.2% $20,461,703 +$734,269 10,942,087 +3.7% Oramed Pharmaceuticals Inc. 17 Feb 2026
SCLX Scilex Holding Co Common Stock, par value $0.0001 per share 4.9% $5,438,249 -$4,921,820 437,510 -48% Oramed Pharmaceuticals Inc. 31 Dec 2025

Schedules 13D/G Reported by ORAMED PHARMACEUTICALS INC.:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.